Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.20
- Piotroski Score 3.00
- Grade Sector Outperform
- Symbol (SAGE)
- Company Sage Therapeutics, Inc.
- Price $5.94
- Changes Percentage (2.24%)
- Change $0.13
- Day Low $5.64
- Day High $5.94
- Year High $28.26
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $28.00
- High Stock Price Target $105.00
- Low Stock Price Target $9.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$8.39
- Trailing P/E Ratio -1.26
- Forward P/E Ratio -1.26
- P/E Growth -1.26
- Net Income $-541,489,000
Income Statement
Quarterly
Annual
Latest News of SAGE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bullock is sending a message to politicians: rate cuts or big spending promises - you can only have one
Reserve Bank governor Michele Bullock's reluctance to lower interest rates indicates a delay in providing relief to borrowers. The RBA's focus on maintaining restrictive settings suggests a cautious a...
By The Guardian | 15 hours ago -
Trump called Megyn Kelly 'nasty' 9 years ago. She just helped deliver his closing message
Megyn Kelly delivered a passionate speech in support of Donald Trump, defending him on various issues during an event in Pittsburgh. Despite past conflicts, Kelly praised Trump's stance on women's pro...
By AP NEWS | 20 hours ago -
Liz Cheney delivers message ahead of election: Women will 'save the day'
Liz Cheney, former Republican Congresswoman, emphasized women's crucial role in the election on The View, supporting VP Kamala Harris over Trump. She highlighted the importance of faithfulness to the ...
By Newsweek | 1 day ago
